Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioma × pazopanib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 30 Neoplasms 11 Sarcoma 8 Carcinoma, Non-Small-Cell Lung 8 Breast Neoplasms 7 Ovarian Neoplasms 6 Neoplasm Metastasis 5 Fallopian Tube Neoplasms 3 Colorectal Neoplasms 3 Recurrence 2 Hemangiosarcoma 2 Financial Stress 2 Clear-cell metastatic renal cell carcinoma 2 Carcinoma, Ovarian Epithelial 2 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Diseases 1 Solid Tumours 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Prostatic Neoplasms 1 Patient Preference 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms, Plasma Cell 1 Melanoma 1 Liver Neoplasms 1 Leiomyosarcoma 1

Interventions

Temozolomide 32 Radiotherapy 11 Bevacizumab 10 Surgical Procedures, Operative 7 IL13-PE38 7 TIC10 compound 6 Lomustine 6 Carboplatin 6 Radiation 5 Chlorotoxin 5 vorasidenib 4 trametinib 4 dabrafenib 4 Valacyclovir 4 OKN 007 4 Flucytosine 4 Dianhydrogalactitol 4 vocimagene amiretrorepvec 3 abemaciclib 3 Paclitaxel 3 Nivolumab 3 Irinotecan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cyclophosphamide 3 CLR1404 3 trans-sodium crocetinate 2 pembrolizumab 2 olutasidenib 2 marizomib 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00350727 2013-04-19

VEG102857

GlaxoSmithKline

Phase 2 Completed

75 enrolled 45 charts

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡